Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > The full article published yesterday

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Feb 16, 2024 9:27am

72 Views

Post# 35883880

RE:RE:The full article published yesterday

Thanks I will look into it over weekend.

palinc2000 wrote: Great post once again!
Are you able to break down what is actually NEW data in this study which appears to be quite extensive.....?

scarlet1967 wrote:
"In conclusion, this is the first in vivo preclinical study to document that administration of TH1902 is better tolerated, based on non-significant mice body weight loss, and more effective than docetaxel at inhibiting tumor growth in an immunocompetent syngeneic “cold” tumor model. Among the salient in vivo findings complementing the TH1902-mediated increase in the infiltration of tumor parenchyma by most classes of leukocytes, was that combining TH1902 with an anti-PD-L1 CPI produced a significantly greater reduction in tumor size than did the combination of anti-PD-L1 with docetaxel. In addition, the survival study reported herein clearly demonstrated that animals treated with TH1902 had a dose-dependent increase in survival, an effect potentiated by co-administration with anti-PD-L1 in a cold tumor model. Finally, the sustained and prolonged effects of TH1902 in our preclinical in vivo studies, even off-treatment and following six cycles, reflects the preliminary Phase 1 observations of prolonged clinical benefits, even after treatment discontinuation."

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1355945/full

This is the full article discussing in details the combo effects of TH1902 and anti PD-L1. Apart from details how and why the combo effect works they are also talking about bystander effects and prolonged off-treatment effects similarly to what they saw in the part 1 and 2 of the phase1 clinical trial.